About Oncotartis, inc.

About company

OncoTartis, Inc. is a private biotechnology company established in 2011. Company’s founding IP came from Prof. Andrei Gudkov’s laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies). Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML). Investigational New Drug application (IND) will be submitted to FDA in the forth quarter of 2017.